Treatment paradigms for the newly diagnosed patient with multiple myeloma

Seminars in Hematology

Volumn 42, Issue SUPPL. 4, 2005, Pages

  Greipp, Philip ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BLEOMYCIN; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ALOPECIA; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; HUMAN; INFECTION; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 28844460391     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.10.002     Document Type: Conference Paper

References (34)

1. M. Attal, J.L. Harousseau, A.M. Stoppa A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 1996 91 97
2. 2 melphalan conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial Blood 99 2002 731 735
3. M. Attal, J.L. Harousseau, T. Facon Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2003 2495 2502
4. J.A. Child, G.J. Morgan, F.E. Davies High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 2003 1875 1883
5. B. Barlogie, S. Jagannath, D.H. Vesole Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 89 1997 789 793
6. J.P. Fermand, P. Ravaud, S. Chevret High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood 92 1998 3131 3136
7. S. Lenhoff, M. Hjorth, E. Holmberg Nordic Myeloma Study Group Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma A population-based study Blood 95 2000 7 11
8. J. Blade, A. Sureda, J. Ribera High-dose therapy autotransplantation/ intensification vs. continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group Blood 98 2001 815a (abstr)
9. Myeloma Trialists' Collaborative Group Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma An overview of 6,633 patients from 27 randomized trials J Clin Oncol 16 1998 3832 3842
10. S. Barille-Nion, B. Barlogie, R. Bataille Advances in biology and therapy of multiple myeloma Hematology (Am Soc Hematol Educ Program) 2003 248 278
11. T. Facon, J.T. Mary, M. Attal Melphalan-prednisone versus dexamethasone-based regimens for newly diagnosed myeloma patients aged 65-75 years. Final analysis of the IFM 95-01 Trial on 489 patients Blood 102 2003 147a (abstr 507)
12. A. Palumbo, A. Bertola, T. Caravita A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs. oral melphalan, prednisone (MP) An interim analysis Haematologica 90 2005 157 (suppl 2, abstr 0398)
13. S.N. Tsiara, E. Kapsali, L. Christou Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients Preliminary data Eur J Haematol 65 2000 118 122
14. D.M. Weber Newly diagnosed multiple myeloma Curr Treat Options Oncol 3 2002 235 245
15. A.A. Chanan-Khan, K.C. Miller, P. McCarthy VAD-t (vincristine, Adriamycin, dexamethasone and low-dose thalidomide) is an effective initial therapy with high response rates for patients with treatment naïve multiple myeloma (MM) Blood 104 2004 943a (abstr 3463) 2004
16. G. Barosi, M. Boccadoro, M. Cavo Management of multiple myeloma and related-disorders Guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) Haematologica 89 2004 717 741
17. P. Tosi, E. Zamagni, C. Cellini Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure Eur J Haematol 73 2004 98 103
18. C. Kyriakou, K. Thomson, S. D'Sa Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well-tolerated and effective regimen in patients with relapsed and refractory multiple myeloma Br J Haematol 129 2005 763 770
19. A. Palumbo, A. Bertola, P. Falco Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma Hematol J 5 2004 318 324
20. S.V. Rajkumar, S. Hayman, M.A. Gertz Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 2002 4319 4323
21. D. Weber, K. Rankin, M. Gavino Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
22. S.V. Rajkumar, E. Blood, D.H. Vesole A randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00) A trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 22 2004 560s (abstr 6508)
23. M. Cavo, E. Zamagni, P. Tosi Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 2005 35 39
24. K.C. Anderson Novel immunomodulatory therapies in the treatment of multiple myeloma Oncology 18 2004 988 990
25. R. Baz, K. Marchant, E.O. Yiannaki Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM) Blood 104 2004 658a (abstr 2397)
26. S.V. Rajkumar, S. Hayman, M.Q. Lacy Combination therapy with CC-5013 (lenalidomide; Revlimid) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM) Blood 104 2004 98a (abstr 331)
27. Protocol ECOG-E4A03. Lenalidomide and dexamethasone with or without thalidomide in treating patients with multiple myeloma. http://www.cancer.gov/ search/ViewClinicalTrials.aspx?cdrid=404161&protocolsearchid= 1344840&version=patient, accessed June 28, 2005
28. SWOG: Phase III randomized study of dexamethasone with or without CC-5013 in patients with newly diagnosed multiple myeloma. http://multiplemyeloma.org/ clinical_trials/ctm/4.04.144.html, accessed June 28, 2005
29. P.G. Richardson, P. Sonneveld, M.W. Schuster Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498
30. S. Jagannath, D. Brian, J. Wolf A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma Blood 104 2005 98a (abstr 333)
31. J.L. Harousseau, M. Attal, X. Leleu Bortezomib (VELCADE) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma Preliminary results of an IFM phase II study Blood 104 2004 416a (abstr 1490)
32. L.M. Wang, D.M. Weber, K. Delasalle VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma Blood 104 2004 64a (abstr 210)
33. H.E. Oakervee, R. Popat, N. Curry PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Br J Haematol 129 2005 755 762
34. R.A. Kyle, S.V. Rajkumar Multiple myeloma N Engl J Med 351 2004 1860 1873